acenocoumarol / Generic mfg. - LARVOL DELTA

Optimization of vitamin K antagonist treatment: Near patient monitoring versus standard of care a parallel group clinical trial in older patients with atrial fibrillation. (PubMed, Eur J Clin Pharmacol) - "NPTM of VKA treatment in AF-patients does not result in an improved TTR when compared to SOC. All-cause death, total number of minor bleedings and all non-major bleedings may be reduced in NPTM, although the study was not powered for these secondary outcomes. Future studies are needed to determine the cost-effectiveness of NTPM versus SOC."

Journal • Atrial Fibrillation • Cardiovascular • Geriatric Disorders

A comparison of antiplatelet and oral anticoagulation strategies to prevent cerebral microembolism after transcatheter aortic valve implantation: the AUREA trial. (PubMed, EuroIntervention) - "In patients without an indication for OAC, an OAC strategy for 3 months post-TAVI did not show any benefit over an antiplatelet strategy in preventing cerebral microembolism. Patients treated with DAPT showed a lower mean volume of brain damage on DW-MRI during the 90 days following TAVI compared to those treated with acenocoumarol."

Clinical • Journal • Cardiovascular • CNS Disorders • Vascular Neurology

Cost-effectiveness of dabigatran for thromboembolic events prevention in atrial fibrillation patients in Chile. (PubMed, Cost Eff Resour Alloc) - "Dabigatran is cost-effective and dominates both rivaroxaban and apixaban at current publicly available prices in Chile. In addition, we expect dabigatran-idarucizumab is also expected to be cost-effective for Chilean health system when is compared against acenocoumarol-PCC as reversal agents."

HEOR • Journal • Atrial Fibrillation • Cardiovascular • Hematological Disorders

Long-Term Outcomes of Valve Replacement With Mechanical Prosthesis in Patients With Valvular Heart Disease: A Single-Center Retrospective Study. (PubMed, Cureus) - "Objective To assess the survival outcomes, postoperative complications, and reoperation rates in patients who underwent prosthetic mechanical valve replacement with acenocoumarol and low-dose aspirin (75 mg), with adequate International Normalized Ratio (INR) monitoring. However, early postoperative risks, especially in women and those with advanced heart failure, highlight the need for individualized care and close monitoring. Future research should aim to refine patient selection, explore sex-based outcome disparities, and optimize anticoagulation strategies to further improve survival and quality of life in this population."

Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Heart Failure

GLANZMANN THROMBASTHENIA AND VENOUS THROMBOSIS : ABOUT 2 CASES (EHA 2025) - "In January 2023, he was admitted for the third episode of melena associated with severe anemia (hemoglobin drop to 5 g/dl) resistant to platelet and red cell transfusions, and continuous infusion of Esomeprazole. This situation necessitated four injections of Novoseven at a dose of 6 mg twice daily for four days, which successfully stopped the bleeding...In 2007, thrombophlebitis of the right lower limb was discovered, and treated with anti-vitamin K (Sintrom*), which was stopped after five months due to recurrent hemorrhagic syndrome and thrombosis permeability... Those observations showed that a severe thrombotic process may occur even in GT.The occurrence of venous thrombosis in our cases is due to the injection of recombinant factor VIIa and the central catheter in one case, and estrogen-progestogen therapy in the second case. The use of unfractionated heparin and low-molecular-weight heparin in the 1st case remains the treatment of choice while the role of new oral..."

Clinical • Anemia • Cardiovascular • Gastroenterology • Hematological Disorders • Pain • Pulmonary Embolism • Respiratory Diseases • Thrombosis

IDENTIFICATION OF NEW MOLECULAR MECHANISMS OF ANTITHROMBIN DEFICIENCY: RESULTS FROM A POLISH COHORT (EHA 2025) - "Thirteen probands (54.2%) received DOAC: six (25.1%) rivaroxaban (20 mg qd), five (20.8%) apixaban (2.5 mg or 5 mg bid) and two (8.3%) dabigatran (150 mg bid). Six probands were under anti-vitamin K treatments: four (16.7%) warfarin (8 or 10 mg qd) and two (8.3%) acenocoumarol (4 mg qd). Finally, four (16.7%) patients received antiplatelet therapy with acetylsalicylic acid (75 mg qd) and one (4.1%) received enoxaparin (150 mg/kg body weight qd).NGS detected SERPINC1 variants in 25 cases (86.2%): 12 missense (48%), 1 new (c.457T>C); 6 small deletions/insertions (24%), 2 new (c.962insG; c.402_403delGA+c.406_408+delGAGG), 5 intronic (20%) and 2 nonsense (8%)... Our study highlights the wide genetic heterogeneity involved in AT deficiency. We identified new genetic defects in SERPINC1, including intronic variants and confirmed the role of retrotransposon insertions as a new under-recognized mechanism contributing to congenital AT deficiency through in the genetic..."

Cardiovascular • Hematological Disorders • Respiratory Diseases • Venous Thromboembolism

Comparison of INR Values Obtained Using a Traditional Method and a Point-of-Care Device (ISTH 2025) - "Methods A total of 182 INR measurements from patients on vitamin K antagonists (acenocoumarol and warfarin) were grouped into three ranges: 1–1.99 (n=82), 2–3.5, (n=79) and >3.5 (n=21). Results The results are summarized in the Table 1 and Table 2High agreement was observed within the therapeutic range (2–3.5), while variability increased at INR levels >3.5, consistent with the sensitivity of thromboplastins to reduced vitamin K-dependent factors such as Factor VII. Table or Figure Upload"

A PHASE IB, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SUBCUTANEOUSLY ADMINISTERED MOSUNETUZUMAB IN PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (EULAR 2025) - P1 | "Four of 15 patients experienced a total of 5 cytokine release syndrome (CRS) events; all were Grade 1-2 and none required tocilizumab administration...One patient receiving concomitant acenocoumarol experienced a transient increase in international normalised ratio due to expected cytochrome P450 inhibition by transient cytokine release, requiring acenocoumarol dose adjustment... Preliminary data from this Phase Ib study indicated that mosunetuzumab exhibits an acceptable safety profile in patients with SLE and that its PK profile in the SLE population is closely aligned with that observed in the relapsed or refractory NHL population. Deep B-cell depletion in the higher-dose cohorts demonstrated the potential for treating B-cell–driven autoimmune diseases. Whilst this study was designed to evaluate the safety and PK profile of mosunetuzumab with a limited dosing regimen, there did appear to be a positive impact on clinical activity."

Clinical • PK/PD data • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Inflammatory Arthritis • Interstitial Lung Disease • Lupus • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Pneumonia • Respiratory Diseases • Systemic Lupus Erythematosus • CD4 • CD8

Obstructive Pharyngo-Laryngeal Hematoma Complicating Oral Anticoagulation: Case Report. (PubMed, Iran J Otorhinolaryngol) - "We present the case of a 74-year-old man who was on oral anticoagulation by acenocoumarol and presented with acute laryngeal dyspnea...Pharyngo-laryngeal hematoma should be considered in patients receiving anticoagulant therapy with symptoms of upper airway obstruction. Drug interactions may be the underlying cause of hypercoagulation, so medications should be carefully prescribed to these patients."

Journal • Hematological Disorders • Pulmonary Disease

Argatroban anticoagulation for heparin induced thrombocytopenia after Heartmate 3 implantation: a single center experience (HEART FAILURE 2025) - "Limited data exist on the management of those patients (most of the published cases use bivalirudin (5–8))...Patients 1 and 2 were successfully bridged to acenocoumarol (International Normalized Ratio range 2-2.5) and discharged without hemocompatibility-related adverse events (Table)...Patients with previous coagulation disturbances may represent a subset of high-risk patients for worse outcomes after HIT regardless of the use of argatroban. It is challenging to distinguish which adverse events are attributable to HIT and argatroban, and which are inherent to LVADs, as these devices themselves carry a high risk of thromboembolism, bleeding, and morbi-mortality."

Clinical • Cardiovascular

Quality of vitamin K antagonist treatment during the last year of life. (PubMed, Hemasphere) - "This decline was more pronounced in cancer patients and acenocoumarol users. In conclusion, the quality of VKA anticoagulation declined in the last year of life in severely ill patients, marked by reduced TTR and increased TAR and VGR, suggesting an increased bleeding risk. These findings highlight the importance of reassessing VKA use and considering discontinuation in patients approaching the end of life."

Journal • Cardiovascular • Heart Failure • Musculoskeletal Diseases • Oncology

Determining Drug Exposure Based on Medication Dispensing Data: A Validation Study of Vitamin K Antagonist Treatment Episodes Against INR Records. (PubMed, Pharmacoepidemiol Drug Saf) - "Fixed methods performed better than dynamic methods when classifying VKA exposure based on dispensing data. Our findings may guide other researchers working with VKA dispensing data, especially when the tablets dispensed or the prescribed dose are unavailable."

Journal

Management of Acenocoumarol in Tunisian elderly population : Risk factors of overdose and bleeding. (PubMed, Ann Cardiol Angeiol (Paris)) - "The use of anticoagulants in the elderly requires a comprehensive assessment, including comorbidities, geriatric settings, and social environment."

Journal • Atrial Fibrillation • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Peptic Ulcer • Renal Disease • Venous Thromboembolism

In vitro-in vivo scaling of cytochrome P450-mediated metabolic clearance using a relative activity factor approach. (PubMed, Drug Metab Dispos) - "We selected multiple probe substrates for CYP1A2 (caffeine, tizanidine, phenacetin), CYP2C9 ((S)-acenocoumarol, glimepiride, lornoxicam, tolbutamide, (S)-warfarin), CYP2C19 ((S)-lansoprazole, omeprazole, pantoprazole), CYP2D6 (desipramine, metoprolol, nebivolol, tolterodine), and CYP3A4 (alprazolam, felodipine, midazolam, nisoldipine, sildenafil, triazolam) to calculate the representative RAF value for each P450 isoform based on the in vivo-to-in vitro clearance ratio of the multiple probe substrates...The fm values of the responsible P450 isoform(s) could be well predicted for mexiletine, tamsulosin, risperidone, celecoxib, and glibenclamide...By applying relative activity factor values obtained from multiple probe substrates, this study was able to quantitatively predict the in vivo clearances mediated by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4. This simple, practical method will help optimize metabolic clearances via the major cytochrome P450..."

Journal • Preclinical • CYP1A2 • CYP2C19 • CYP2C9 • CYP3A4

Impact of Ginkgo biloba drug interactions on bleeding risk and coagulation profiles: A comprehensive analysis. (PubMed, PLoS One) - "However, interactions with anticoagulants including direct oral anticoagulants and acenocoumarol, were not statistically significant in our analysis...Specific medications, including clopidogrel, aspirin, celecoxib, loxoprofen, nifedipine, and omeprazole, were significantly associated with the risk of bleeding and abnormal coagulation (p <  0.05). Interactions with ticagrelor, etoricoxib, insulin, omeprazole, and domperidone were associated with abnormal coagulation tests without affecting the reported bleeding. These findings underscore the critical need of evaluating potential interactions involving Ginkgo biloba extract drug interactions in clinical pratice, particularly when assessing bleeding risk and managing coagulation."

Journal • Observational data • Retrospective data • Hematological Disorders

Long-term left ventricular thrombosis resolution in patients receiving vitamin k antagonists: a multicenter observational study. (PubMed, Intern Emerg Med) - "Incidence of LVT resolution appeared to be higher at 12 than at 3 and 6 months of follow-up, and the rates of on-treatment acute arterial and bleeding events were low. Reduced left ventricular ejection fraction and left-ventricular aneurysm appeared to be associated with a lower rates of LVT resolution."

Journal • Observational data • Cardiovascular • Hematological Disorders • Ischemic stroke • Myocardial Infarction • Thrombosis • Venous Thromboembolism

Bowel obstruction and anticoagulation, is there a link? (APASL 2025) - "She was under treatment with Acenocoumarol for paroxysmal atrial fibrillation...Conclusion Our case offers two important implications for clinical practice. First, colonic intramural hematoma may occur in patients receiving anticoagulant therapy, while it remains rare and its endoscopic and radiological features remain poorly described in the literature."

Anemia • Atrial Fibrillation • Cardiovascular • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Myocardial Infarction • Oncology • Pain

Epidemiology And Clinical Features Of Vascular Liver Diseases Secondary To Myeloproliferative Disorders In Morocco: A Monocentric Experience (APASL 2025) - "Therapeutic management was instituted and consisted of Hydroxycarbamide for the myeloproliferative disorder for 12 patients (48 %). As for anticoagulants, only 15 patients (60 %) received acenocoumarol, among which 5 patients (20 %) switched to rivaroxaban... Despite their relatively low prevalence, vascular diseases of the liver represent a significant health problem in the field of liver disease. Our study shows that almost 20 % of these diseases are secondary to myeloproliferative disorders, mainly due to portal thrombosis, with a clear female predominance. Early management is necessary to reduce the risk of morbidity and mortality."

Clinical • Acute Myelogenous Leukemia • Anemia • Cardiovascular • Chronic Myeloid Leukemia • Essential Thrombocythemia • Fatigue • Fibrosis • Gastrointestinal Disorder • Hematological Disorders • Hepatology • Immunology • Leukemia • Liver Cirrhosis • Myelofibrosis • Myeloproliferative Neoplasm • Pain • Portal Hypertension • Thrombocytosis • Thrombosis • JAK2

Progressive coronary aneurysms in Kawasaki disease: A case report and long-term follow-up. (PubMed, Radiol Case Rep) - "Despite initial treatment with intravenous immunoglobulin, aspirin, low molecular weight heparin, and subsequent acenocoumarol therapy, the patient experienced progressive thrombosis of the intraventricular artery aneurysm over 3 years. This case underscores the critical need for early imaging, timely diagnosis, and long-term monitoring of KD patients, as coronary aneurysms may persist or progress despite prompt therapy. Rigorous follow-up, tailored anticoagulation strategies, and regular imaging are essential to minimize the risk of life-threatening cardiovascular complications."

Journal • Cardiovascular • Conjunctivitis • Hematological Disorders • Ocular Infections • Ocular Inflammation • Ophthalmology • Thrombosis • Vasculitis

Avascular Necrosis of the Femoral Head in Patients with Antiphospholipid Syndrome: A Case Series. (PubMed, Hematol Rep) - "The patient was given clopidogrel and acenocoumarol. She was treated with acenocoumarol. AN is a rare clinical manifestation of APS, which may precede the diagnosis of APS for many years."

Journal • Cardiovascular • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis • Ischemic stroke • Obstetrics • Otorhinolaryngology • Rheumatology • Thrombosis • Vertigo • MTHFR

Hemorrhage risk associated with triple antithrombotic therapy: a focused real-world pharmacovigilance disproportional analysis study. (PubMed, BMC Cardiovasc Disord) - "This study highlights the elevated hemorrhage risk associated with TAT, particularly with rivaroxaban, while apixaban appears safer in terms of bleeding and mortality. These findings underscore the need for cautious monitoring of bleeding outcomes with anticoagulant regimens, particularly rivaroxaban combinations for optimizing patient outcomes. However, the signals obtained in this study need to be validated in future trials."

Adverse events • Clinical • Journal • Real-world evidence • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders

Cost-effectiveness of direct oral anticoagulants in non-valvular atrial fibrillation. (PubMed, Gac Sanit) - "Based on the analysis of data from clinical practice and the similarity of results using several different techniques to adjust for bias associated with observational studies, we conclude that DOAC would be an efficient alternative for the treatment of patients with NVAF."

HEOR • Journal • Atrial Fibrillation • Cardiovascular

Clinical Outcome and Costs Based on the Degree of Vitamin K Antagonist Control for Non-Valvular Atrial Fibrillation. (PubMed, J Clin Med) - "The cost arising from patients with adequate control was lower than that for patients with inadequate control. Strategies to improve anticoagulation control could improve health outcomes and costs."

Clinical data • Journal • Atrial Fibrillation • Cardiovascular • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders

Treatment of functioning insulinoma using endoscopic ultrasound-guided radiofrequency ablation. (PubMed, Rev Esp Enferm Dig) - "Acenocoumarol was discontinued three days prior to the procedure and replaced with enoxaparin at 40 mg daily, with the basal anticoagulant therapy being restarted 24 hours after the procedure. Ten days later, the patient was diagnosed with an acute hematoma in the tail of the pancreas and gastric body, which led to clinical signs of hypotension and acute anemia, requiring the discontinuation of anticoagulation once again. Therefore, we believe that caution should be taken when managing anticoagulant therapy in patients undergoing endoscopic ultrasound (EUS)-guided radiofrequency ablation."

Journal • Hematological Disorders • Hypotension • Solid Tumor

Cost-effectiveness of apixaban in non-valvular atrial fibrillation (NVAF) based on effectiveness data from a Spanish study in clinical practice (real-world evidence). (PubMed, Expert Rev Cardiovasc Ther) - "The probability of apixabanbeing cost-effective ranges from 91.1% (vs dabigatran 150 mg), 97.8% (vsdabigatran 110 mg), and 100% (vs. rivaroxaban, edoxaban, and acenocoumarol). Based on the results of the FANTASIIA study, apixaban is acost-effective treatment (below a willingness to pay of €25,000 per QALYgained) compared to dabigatran, rivaroxaban, edoxaban, and acenocoumarol intreating patients with NVAF."

HEOR • Journal • Real-world evidence • Atrial Fibrillation • Cardiovascular